Company Hexima Limited

Equities

HXL

AU0000111932

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Company contact information

Sector

Annual profits - Rate of surprise

Sector Other Biotechnology & Medical Research

Market Closed - Australian Stock Exchange Other stock markets 07:40:34 2023-12-07 pm EST			5-day change	1st Jan Change
0.018 ^AUD	0.00%		-21.74%	-10.00%

Nov. 29	Hexima Limited Announces the Resignation of Dr. Nicole Van Der Weerden as Director	CI
Sep. 19	Hexima Limited Appoints Phillip Hains as A Non-Executive Director	CI

Hexima Limited is an Australia-based clinical-stage, anti-infectives focused biotechnology company. The Company is engaged in the research and development of plant defensin peptides for applications in human therapeutics. Its lead drug candidate is the plant defensin, pezadeftide, developed for the treatment of fungal nail infections. The Company is conducting phase II clinical trial testing pezadeftide as a treatment for onychomycosis. Its Antifungal Plant Defensin Technology platform is engaged in identifying several plant peptides with potent antifungal activity against a broad range of human fungal pathogens. It is also investigating the application of its plant defensin technology to other human fungal diseases.

AUD in Million	2022	Weight	2023	Weight	Delta
Plant-derived Proteins 100.0 %	6	100.0 %	1	100.0 %	-74.45%

AUD in Million	2022	Weight	2023	Weight	Delta
Australia 100.0 %	6	100.0 %	1	100.0 %	-74.45%

Managers	Title	Age	Since
Nicole van der Weerden CEO	Chief Executive Officer	-	2014
Leanne Ralph SEC	Corporate Secretary	-	2021

Members of the board	Title	Age	Since
Nicole van der Weerden CEO	Chief Executive Officer	-	2014
Zhen Nan Yap BRD	Director/Board Member	-	2018

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	167,039,629	60,411,535 ( 36.17 %)	0	36.17 %

Hexima Ltd.

La Trobe Institute for Molecular Sci La Trobe University

3086, Melbourne

http://www.hexima.com.au

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
HEXIMA LIMITED	-10.00%	2 M $
SEAGEN INC.	+70.40%	41 313 M $
IQVIA HOLDINGS INC.	+5.07%	39 289 M $
MODERNA, INC.	-55.28%	30 625 M $
LONZA GROUP AG	-27.34%	27 758 M $
ICON PUBLIC LIMITED COMPANY	+40.26%	22 431 M $
ALNYLAM PHARMACEUTICALS, INC.	-28.45%	21 339 M $
CELLTRION, INC.	+4.49%	17 693 M $
UNITED THERAPEUTICS CORPORATION	-13.10%	11 356 M $
BIO-TECHNE CORPORATION	-17.58%	10 803 M $

Other Biotechnology & Medical Research